Medipost to acquire 8.0% stake in US unit MEDIPOST, Inc. for ₩20.0bn

Medipost · KOSDAQ · 078160 · Oct 29, 2026 · Equity acquisitions and disposals

Medipost filed to acquire 15,000,000 shares of MEDIPOST, Inc. (US) for ₩20.0bn, equal to 8.0% of equity. After the deal, Medipost's stake will be 100.0%, with the acquisition expected on Nov 30, 2026, to fund R&D and operating costs for the US Phase 3 clinical trial and commercialization of 'Cartistem' for knee osteoarthritis.

Key facts

Target companyMEDIPOST, Inc. (US)
Shares15,000,000 shares
Deal amount₩20.0bn
% of equity8.0%
Stake after100.0%
PurposeAdditional capital contribution for R&D costs of the US Phase 3 clinical trial and operating funds for the US commercialization of 'Cartistem', a stem cell therapy for knee osteoarthritis
Expected dateNov 30, 2026

Comparison

Amount as % of FY2025 revenue (calculated)27.2%
Revenue 2025₩73.7bn
Revenue 2024₩70.7bn
Revenue 2023₩68.6bn

Context

By our calculation, the amount equals 27.2% of FY2025 revenue.

Source: DART (Financial Supervisory Service) · Original filing on DART ↗ (opens the Financial Supervisory Service's DART site)